Gilead Sciences (GILD) 2024年CSR報告「NASDAQ」.pdf

《Gilead Sciences (GILD) 2024年CSR報告「NASDAQ」.pdf》由會員分享，可在線閱讀，更多相關《Gilead Sciences (GILD) 2024年CSR報告「NASDAQ」.pdf（40頁珍藏版）》請在三個皮匠報告上搜索。

1、Appendix2024 R E S P O N S I B L E B U S I N E S S A N D I M PA C T R E P O R T22024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactAbout This DocumentThis Reporting Appendix is a stand-alone companion publication to our 2024 Responsible Business and Impact Report,which

2、highlights Gileads related activities,performance and data.It supplements the information in Gileads 2024 Responsible Business and Impact Report with the following sections:Corporate Responsibility at Gilead Our Supply Chain Investments Our Approach to Tax Aligning With the United Nations Sustainabl

3、e Development Goals Environmental Data Global Reporting Initiative(GRI)Index 2021(reporting“with reference to”)Sustainability Accounting Standards Board(SASB)Biotechnology&Pharmaceuticals Standard 2018We endeavor to align our data collection,measurement and reporting activities with industry-leading

4、 environmental,social,governance(ESG)-related performance frameworks,including the United Nations Global Compact(UNGC),United Nations Sustainable Development Goals(UN SDGs)and CDP Corporate Questionnaire.The scope of Gileads 2024 Responsible Business and Impact Report and this Reporting Appendix inc

5、ludes all entities listed in Gileads 2024 Annual Report on Form 10-K and focuses primarily on our fiscal year ending Dec.31,2024.This Appendix is intended to highlight some of the companys responsible business efforts during the fiscal year ended Dec.31,2024;it is not a comprehensive description or

6、representation of all of the companys responsible business activities during that time.Unless otherwise noted,quantitative and qualitative data aligns with our fiscal year.Some qualitative information from both before and shortly after our fiscal year is also included.At the time of publication,quan

7、titative environmental data covers our fiscal year ending Dec.31,2023,due to data collection and external assurance cycles.Fiscal year 2024 environmental data will be posted on G when it is available,typically in the second fiscal quarter.See also our stand-alone Task Force on Climate-Related Financ

8、ial Disclosures Summary ReportLauren BennettLegalE NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTAXAB OU TRESPONSIBILITYThe content featured in this report focuses on Responsible Business topics material to Gileads business operations.The phrase“materiality”as used in the context of this report and o

9、ur materiality review process is different than the definition used in the context of our filings with the U.S.Securities and Exchange Commission(SEC)or any other laws or requirements that may apply to us.Issues deemed material for purposes of this report and for purposes of determining our Responsi

10、ble Business strategies may not be considered material for SEC or any other mandatory reporting purposes.Within this Reporting Appendix and our 2024 Responsible Business and Impact Report,we are using the following terms to represent various aspects of our Responsible Business efforts:“Responsible B

11、usiness,”“ESG,”“Corporate Responsibility”and“Sustainability.”32024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactCorporate Responsibility at GileadACTIVE LEADERSHIP AND BOARD INVOLVEMENT Gileads Corporate Responsibility Committee(CRC)is responsible for the strategic dir

12、ection,accountability and review of the impact of our ESG activities.The CRC comprises leadership across Public and Government Affairs,Human Resources,Legal,Finance,Medical Affairs,Commercial and Manufacturing.These cross-functional executives are responsible for obtaining wide organizational buy-in

13、 while also providing regular feedback to Gileads senior leadership team and Board of Directors about ESG activities.Our Nominating and Corporate Governance Committee of the Gilead Board of Directors has primary oversight of our ESG program as part of its charter.Our full Board exercises risk oversi

14、ght directly and through its committees.The committees,as well as management,provide regular updates on delegated areas of oversight,specific ESG material risks and legal developments.To further demonstrate Gileads robust oversight of our corporate responsibility and sustainability efforts,the major

15、ity of our Board members have ESG experience.Our management-led CRC meets quarterly and is tasked with managing ESG issues and,in consultation with senior leadership,driving forward our ESG goals and strategy.Our ESG activities are guided by the Gilead Code of Ethics,which focuses on the most import

16、ant principles and expectations about how we should work with our customers,third parties,business partners and each other.E NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTAXA BO U TRES PONS IBILITYBoard of Directors Composition55%5 of 9 board members have ESG skills and experienceESG EXPERIENCE*44%4

17、of 9 board members identify as ethnically diverseETHNICITY33%3 of 9 board members identify as womenGENDER*Has had direct responsibility for ESG issues as demonstrated by experience as a Chief Sustainability Officer,Corporate Secretary,Chair of a related committee (e.g.,Governance,Sustainability,Corp

18、orate Responsibility)or Chief Executive Officer of a company with leading ESG practices.Shreya JaniPublic Affairs42024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactGILEADS ESG GOVERNANCE STRUCTUREBoard of DirectorsCorporate Responsibility CommitteeSets vision,ambition

19、and strategy and oversees implementation and disclosureCorporate Responsibility Working GroupImplements strategy,tracks progress,reports results and provides recommendations to the Corporate Responsibility CommitteeInnovation LeadsRecommends goals and initiatives,implements and tracks progressAccess

20、 and Health Equity LeadsRecommends goals and initiatives,implements and tracks progressPeople and Culture LeadsRecommends goals and initiatives,implements and tracks progressEnvironment LeadsOversees the Sustainability Committee,recommends goals and initiatives,implements and tracks progressGilead L

21、eadership TeamEndorses material ESG goals and initiativesNominating and Corporate Governance CommitteeOversees corporate governance policies and practices of GileadE NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTAXA BO U TRES PONS IBILITY52024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIX

22、INNOVATE for ImpactEXTERNAL STAKEHOLDERSPeers and Business PartnersPartnersPeersSuppliersGeneric drug manufacturersInvestors and Risk AssessorsStockholders Institutional investors and analystsBankers and insurersESG ratings and indicesRulemakers and WatchdogsGlobal NGOsRegulatorsAcademic institution

23、sIndustry associationsMediaCustomer and CommunityHealthcare providersInsurance providersPatientsCommunitiesSarika Mujumdar,Samantha StrongMedical AffairsMANAGEMENT,STAKEHOLDER ENGAGEMENT AND MATERIALITYGilead regularly monitors our operations to reduce potential or actual negative ESG material impac

24、ts,both internal and external.Business leaders with direct oversight over each topic area are responsible for managing these impacts,and internal and external stakeholders conduct annual evaluations to identify strengths and areas for improvement.Internal Stakeholders To review potentially relevant

25、ESG-related topics,we assembled a team of internal stakeholders from across Gilead,representing Corporate Sustainability,Public Affairs,Gilead Patient Solutions,Pharmaceutical Development and Manufacturing,Global Value and Access,Research,Environmental Health and Safety,Accounting,Human Resources,Le

26、gal,Tax,Investor Relations and Regulatory Affairs.E NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTAXA BO U TRES PONS IBILITY62024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactESG MATERIALITYThrough our ESG materiality assessment,business leaders from across the company

27、asessed and ranked ESG material topics for our ESG program based on the level of Gileads internal or external influence,our relative impact,peer evaluations and due diligence.MATERIAL TOPICS ENVIRONMENTAL A Climate change and energy B Manufacturing and supply chain management C Pollution and effluen

28、ts D Waste and packaging E Materials sourcing and use F Water stewardship SOCIAL A Access and availability of medicines B Affordability and pricing C Employee recruitment,development and retention D R&D for unmet medical needs E Public health F Employee engagement and culture G Inclusion H Philanthr

29、opy and community relations I Employee wellness J Occupational health and safety K Health education and prevention L Health system strengthening M Fair working conditions GOVERNANCE A Corporate governance B Product quality and safety C Innovation technologies D Corruption and bribery E Intellectual

30、property F Clinical trial conduct G Data privacy and security H Tax and fair contribution to society I Counterfeit and illicit tradeJMLFFDCGHIBASTAKEHOLDER PERSPECTIVE(Degree of Stakeholder Concern)GILEAD PERSPECTIVE(Potential Impact on Business)Increasing ImportanceIncreasing ImportanceKIDHEBCEFAGC

31、DBAEE NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTAXA BO U TRES PONS IBILITY72024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactOur Supply Chain InvestmentsGileads supply chain consists of hundreds of direct suppliers and thousands of indirect suppliers in various geog

32、raphies.We expect both our direct and indirect suppliers and business partners to share our commitment to ethics and compliance,and to read,understand and follow the Gilead Supplier Code of Conduct.And we collaborate with them to address issues,build capacity and achieve shared goals.The Supplier Co

33、de of Conduct is included in our standard purchase order terms and conditions.By the end of 2024,we were more than halfway to our 2025 goal of 90%(based on spend)of our direct and indirect suppliers having attested to our Supplier Code of Conduct.SUPPLIER EXCELLENCESupplier Excellence is one of our

34、core strategic procurement pillars and serves as an important lever in establishing effective engagements and consistent standards with Gilead suppliers and service providers.In support of this pillar,we employ a comprehensive framework to guide the supplier engagement life cycle.This framework is d

35、esigned to drive enhanced performance and responsible sourcing,mitigate risks,support compliance,and foster supplier development,collaboration and innovation.We implemented a systematic,multifactor methodology in 2024 to segment our existing suppliers as part of ongoing refinement of our Supplier Ex

36、cellence framework.This segmentation process further enables us to conduct thorough diligence via risk and performance management assessments for our key suppliers,facilitating more informed decision-making and strategic planning.We are dedicated to integrating Gileads sustainability commitments and

37、 practices into our relationships with suppliers and service providers,including initiatives focused on supplier inclusion and decarbonization.To learn more about our supplier programs and standards for conducting business with Gilead,visit our Supplier Information website.SUPPLIER INCLUSIONWe are c

38、ommitted to creating and fostering an inclusive and high-performing supplier base.We do so by striving to create equal opportunity for all suppliers to compete for our contracts and striving to make sure our pool of potential suppliers comprises businesses of all sizes and backgrounds,including smal

39、l businesses and businesses owned by women,minorities,U.S.veterans,people with disabilities and members of the LGTBQ+community.Regardless of background,we always seek to select the supplier who is best able to work with us to achieve Gileads business objectives.We believe supplier inclusion is a str

40、ategic business imperative that generates a competitive advantage,increases access to innovation,enables greater agility in our supply chain and supports socioeconomic inclusion across our society.E NVIR O NM E NTAL DATAG R ISAS BS UPPLY CH AINTAXA BO U TRESPONSIBILITYGilead Pediatric Center of Exce

41、llenceDublin,Ireland82024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactHELPING TO PROVIDE ACCESS TO GENUINE MEDICINES The proliferation of counterfeit medicines puts the health and safety of people who depend on life-changing treatments at grave risk.Even with dedicate

42、d resources and commitments by industry and law enforcement to keep people safe from counterfeits,criminals exploit vulnerabilities in current supply chain regulations.Gilead is committed to protecting patients and global public health from bad actors selling counterfeit,adulterated and other illici

43、t versions of our medicine.To help individuals worldwide access the authentic Gilead medicines they have been prescribed,Gilead maintains a Global Product Security group that leads an inclusive,cross-functional Anti-Counterfeiting Task Force consisting of legal,quality,regulatory,trades,global seria

44、lization and traceability,security,supply chain,packaging and other Gilead professionals.Gileads work to provide safe,unaltered medicines for patients involves working with law enforcement globally and taking swift and direct legal action when needed.Gileads efforts to monitor,detect and investigate

45、 illegal activity threatening patient safety can end in raids of illegal counterfeiting operations.In 2024,Gileads efforts led to eight raids,10 arrests,over 200 Gilead-branded counterfeit medicines seized,and over 6,000 other counterfeit medicines and medicine components seized,helping to protect p

46、atient trust in Gilead medicine.We believe protecting global public health,patients and their trust in our company is a social responsibility that supports our health equity mission.To learn more about how Gilead is investing beyond expectations to support patient safety and reduce the availability

47、of counterfeit medicines,please visit our website.QUANTIFYING SUPPLIER INCLUSION ECONOMIC IMPACTPromoting a more inclusive supply chain furthers Gileads efforts to deliver positive impacts for the communities where we work and live.In 2024,these efforts significantly supported and contributed to the

48、 broader U.S.economy.9.7K Jobs supported in total Total full-time,part-time and seasonal jobs supported by the Gilead supply chain of small and diverse suppliers through direct,indirect and induced impacts.$1.2B Total value addedTotal U.S.GDP contributed by the Gilead supply chain of small and diver

49、se suppliers through direct,indirect and induced impacts.$701M Total wagesTotal value of wages,salaries and benefits supported by the Gilead supply chain of small and diverse suppliers through direct,indirect and induced impacts.$2.15B Total outputTotal value of goods and services produced to satisf

50、y the Gilead supply chain of small and diverse suppliers through direct,indirect and induced impacts.Supplier Engagement on Environmental SustainabilityWe view our suppliers as extensions of our business.As such,we engage with them on Scope 3 greenhouse gas(GHG)emissions and other environmental foot

51、print topics.See Pages 65-66 of our 2024 Responsible Business and Impact Report to learn more about how were working with key suppliers on gathering footprint data,GHG reduction targets and plans and other initiatives.E NVIR O NM E NTAL DATAG R ISAS BS UPPLY CH AINTAXA BO U TRESPONSIBILITY92024 RESP

52、ONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactOur global tax strategy is designed to be in line with Gileads general framework of maintaining a low-risk tolerance level in the countries in which we operate.Our strategy focuses on:Putting in place appropriate levels of gover

53、nance,risk management and accountability Complying with tax laws in a responsible manner Having open and constructive conversations with stakeholders,including governments and tax authoritiesThis strategy guides our approach to tax compliance.We are committed to paying our fair share of tax,and we s

54、eek to comply with applicable laws,rules and regulations in meeting our tax compliance and reporting responsibilities.Accordingly,we pay a variety of taxes,including corporate income taxes,customs duties,excise taxes,stamp duties,employment and other business taxes in these jurisdictions,in our effo

55、rts to comply with local law.We also withhold and pay employee taxes and indirect taxes,such as the Value Added Tax.This strategy also guides our approach to tax planning.We analyze the potential tax implications with a focus on clarifying business tax consequences in locations where we operate in o

56、rder to enhance compliance and business alignment.TAX GOVERNANCE,CONTROL AND RISK MANAGEMENTOur management is responsible for establishing and maintaining robust internal controls that govern our tax policies and financial reporting procedures,including management of associated risks.Under this syst

57、em,key tax processes are reviewed by our internal and external auditors for adherence.Our Chief Financial Officer and Board Audit Committee receive updates on at least a quarterly basis.Our Approach To TaxDespite our strong governance,a level of risk associated with tax compliance naturally exists b

58、ecause tax law is inherently complex and can result in a variety of interpretations with respect to how our operations are taxed.Our tax processes and procedures are designed to mitigate such risks.Among other processes and procedures,transactions between our affiliated companies are guided by the a

59、rms length standard as set out by the Organisation for Economic Co-operation and Development(OECD)guidelines for international tax matters.Certain significant planning proposals are discussed with and approved by our executive management,Chief Financial Officer and the Board Audit Committee.Where ap

60、propriate,we seek high-quality external advice on tax consequences of business transactions.Moreover,all Gilead employees are responsible for upholding Gileads Core Values and Code of Ethics.Employees receive training on Gileads Core Values and Code of Ethics,which includes specific reporting proced

61、ures for any suspected violations.Discovery PathGilead campus,Foster City,CaliforniaE NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTA XA BO U TRESPONSIBILITY102024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactSTAKEHOLDER ENGAGEMENT AND MANAGEMENT OF CONCERNS RELATED TO

62、TAXWe engage with tax authorities with honesty,integrity,respect and fairness and in a spirit of cooperative compliance.Our tax positions and filings are subject to review and audit by tax authorities in jurisdictions where we conduct business.In the course of such a review,we strive to be transpare

63、nt with tax authorities,providing relevant facts and documentation to support our tax positions and to resolve disputes constructively and in a timely manner on current,future and past tax risks.Where appropriate,we also seek to proactively engage with tax authorities on their interpretation of loca

64、l tax laws and their application to our specific facts and circumstances.New tax laws and regulations often bring uncertainty in their interpretation and application,and inconsistent treatment of a transaction by different jurisdictions brings the risk that the same income may be taxed by two or mor

65、e tax authorities.In those situations,we also seek to work with tax authorities in a transparent manner to mitigate or,if possible,prevent double taxation of our economic profits,in compliance with tax treaties and applicable national legislation.We monitor proposals and changes to tax incentives an

66、d regulations in the countries in which we operate in order to assess their impact on our business.From time to time,Gilead may collaborate with taxpayer advocacy groups so that Gileads views are considered during the public discourse.We also periodically support initiatives to increase public trust

67、 and transparency in national and international tax regimes.Chan CheaTaxE NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTA XA BO U TRESPONSIBILITY112024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for Impact2024 TAX AND JURISDICTIONAL DATAThe following charts have been prepared t

68、o provide more insight into Gileads tax profile.These numbers and figures follow Gileads accounting policy as outlined in our 2024 Annual Report on Form 10-K(Note 1:Summary of Business and Significant Accounting Policies).Tax jurisdictional data is determined based on the activities of Gileads subsi

69、diaries that are tax resident in said jurisdiction.United States:$1,908MRest of the World:$1,052MIncome tax incurred:$2,053MIndustry specific taxes:$508MPayroll taxes:$341MProperty taxes:$53MOther taxes:$5MThis chart details the taxes incurred by type of tax and highlights that Gilead pays a signifi

70、cant amount of tax beyond corporate income tax.In addition to payroll taxes and other indirect taxes,Gilead incurred significant amounts of industry-specific taxes such as the U.S.Branded Prescription Drug Fee.TAX INCURRED BY TYPEThis chart details the taxes incurred by jurisdiction.A significant pr

71、oportion of Gileads taxes are paid to the United States,which is where Gileads headquarters and the majority of our research and development jobs are located.TAX INCURRED BY JURISDICTIONE NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTA XA BO U TRESPONSIBILITY122024 RESPONSIBLE BUSINESS AND IMPACT REP

72、ORT:REPORTING APPENDIXINNOVATE for ImpactUnited States:$20,619MRest of the World:$8,136MUnited States:$4,787MRest of the World:$627MUnited States:$163MRest of the World:$1,825MUnited States:10,862Rest of the World:6,785REVENUE BY JURISDICTIONFIXED ASSETS BY JURISDICTIONOPERATIONAL PROFIT BY JURISDIC

73、TIONEMPLOYEES BY JURISDICTIONThese charts indicate key Gilead metrics by jurisdiction.Gilead primarily earns its revenue and profit in the United States,and the assets and employees that generate those financial metrics are also predominately located in the United States.This is reflective of Gilead

74、s tax policy whereby profits are aligned with the assets,functions and risks associated with each jurisdiction.E NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTA XA BO U TRESPONSIBILITY132024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactALIGNING WITH THE UNITED NATIONS S

75、USTAINABLE DEVELOPMENT GOALSGilead supports all of the 17 UN SDGs.We believe our business activities are most aligned with the UN SDGs below.GOOD HEALTH AND WELLBEINGWe deliver innovative therapies that offer new hope for patients and seek to make our therapies broadly available to people living wit

76、h,or at risk from,life-threatening conditions.We go beyond the medicine and help promote access to care for all communities.Our ambitions have led us to a cure for hepatitis C and to transforming the treatment and prevention of HIV.We continue to set our sights on curing more viral diseases and cert

77、ain cancers and inflammatory diseases.QUALITY EDUCATIONWe educate and train healthcare providers on advanced therapies,including in resource-limited countries.One example is Gileads Research Scholars Program that supports innovative research from emerging investigators around the world to incorporat

78、e new perspectives in our pursuit of scientific understanding and progress.To learn more,please click here.GENDER EQUALITYWe strive to cultivate an inclusive workforce comprised of skilled employees of all backgrounds,experiences and perspectives,and we seek to empower all to thrive and succeed.This

79、 is exemplified by our equal pay practices and global pay ratio,which seek to promote equal pay for equal work.CLEAN WATER AND SANITATIONWe have committed to achieve water neutrality in water-stressed regions by 2030 and to reduce potable water use at owned facilities by 30%by 2030.We also responded

80、 to the water-related section of the CDP Corporate Questionnaire in 2024 for our first time and received a B-score.To learn more about our efforts to reduce water consumption,please visit Pages 71-73 of our 2024 Responsible Business and Impact Report.AFFORDABLE AND CLEAN ENERGYWe generate and purcha

81、se renewable energy to offset grid-supplied energy at some of our worldwide facilities.We have committed to 100%renewable electricity in our operations by 2025 and to transitioning 100%of our fleet to electric or low-emissions vehicles and increasing charging infrastructure by 2030.In February 2025,

82、Gilead along with three other partners,collaborated to execute an aggregated purchase of 245 GWh of renewable energy per year in Spain for a 10-year term.E NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTA XA BO U TRESPONSIBILITY142024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE f

83、or ImpactINDUSTRY,INNOVATION AND INFRASTRUCTUREWe leverage science and innovation to develop industry-leading therapeutics for areas of unmet medical need.REDUCED INEQUALITIESGilead is committed to building a culture where employees feel respected and proud to work at Gilead.Gilead has various progr

84、ams and initiatives that seek to empower all employees to thrive and succeed,including its High Impact Leadership Skills(HILS)Program and Employee Resource Groups and other professional development opportunities that are open to all.Gilead is also committed to breaking down barriers to health access

85、 and supporting inclusion of broad populations in clinical trials and public health initiatives.RESPONSIBLE CONSUMPTION AND PRODUCTIONWe aspire to the following:By 2030,reduce total solid waste generated(nonhazardous only,excludes construction and demolition waste)by 20%compared to 2019,including el

86、imination of single-use plastics(excluding manufacturing and R&D operations),and achieve zero-waste status through diversion programs.We are also increasing secondary and tertiary product package composition to 30%post-consumer recycled plastic content and 70%recycled content paper from sustainably

87、managed forests by 2025.For more information on our environmental sustainability targets,see Page 63 of our 2024 Responsible Business and Impact Report.CLIMATE ACTIONWe aspire to reducing absolute GHG emissions across our direct operations(Scope 1 and 2)by 46%,and across our value chain(Scope 3)by 1

88、5%,by 2030,from a 2019 baseline.We have committed to 100%renewable electricity in our operations by 2025 and to transitioning 100%of our fleet to electric or low-emissions vehicles and increasing charging infrastructure by 2030.Collectively,these efforts seek to achieve our ambition of net-zero oper

89、ational greenhouse gas emissions by 2030.PARTNERSHIPS FOR THE GOALSWe forge internal and external partnerships to improve patient care,strengthen health systems and reduce our environmental impact.E NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTA XA BO U TRESPONSIBILITY152024 RESPONSIBLE BUSINESS AND

90、 IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactSCOPE 1 AND 2 GHG EMISSIONS Metric tons CO2e(mt CO2e)20192020202120222023Scope 154,09848,63055,10455,91956,096 Mobile 19,53910,90614,11818,91520,382 Fugitive/Refrigerants8801,3232,6121,0782,033 Stationary33,67936,40138,37435,92633,681Scope 2(market

91、-based)33,33132,13234,29726,29122,339 Electricity33,33132,06534,25226,25122,260 Heat/Steam/Cooling*67454080Scope 2(location-based)55,24852,52656,34757,25553,778Scope 1 and 2(market-based)87,42980,76289,40182,21078,435Scope 1 and 2 percent change from 2019N/A-8%2%-6%-10%Data Coverage(as a percentage

92、of global full-time employees)100%100%100%100%100%GHG EMISSIONS INTENSITY (Scope 1 and 2)Kilograms CO2e per square foot(kg CO2e/sq.ft.)20192020202120222023Scope 17.496.046.716.616.54Scope 2(market-based)4.613.994.183.112.60Scope 2(location-based)7.656.536.866.776.27Environmental DataThe tables below

93、 present our environmental performance data from 2019-2023.We will publish 2024 environmental data on our website,which may reflect updates to the data contained in the following tables.E N V I R O N M E N TA L DATAG R ISAS BSUPPLY C HAINTAXA BO U TRESPONSIBILITY*Data not collected or reported162024

94、 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactSCOPE 3 GHG EMISSIONS Metric tons CO2e(mt CO2e)20192020202120222023Purchased Goods and Services2,5608,432834,264785,443858,104828,191Capital Goods2,598,941129,30284,328119,05167,687Fuel-and Energy-Related Activities1,314,82

95、114,47417,12016,25215,219Upstream Transport&Distribution1,2,3,553,05173,60568,44587,57668,315Waste1,35,1664,4644,7283,8843,300Business Travel(required only)1,2,3,550,2908,6158,12338,14656,569Employee Commuting1,223,6567,56515,02330,04639,143Upstream Leased Assets4N/AN/AN/AN/AN/ADownstream Transport&

96、Distribution1192178218167126Processing of Sold Products4N/AN/AN/AN/AN/AUse of Sold Products4N/AN/AN/AN/AN/AEnd of Life Treatment of Sold Products1,677777Downstream Leased Assets4N/AN/AN/AN/AN/AFranchises4N/AN/AN/AN/AN/AInvestments1,2238,32679,47751,01249,47143,241Total Scope 3 GHG Emissions1,092,882

97、1,151,9511,034,4471,202,7041,121,798Scope 3 GHG Emissions FootnotesScope 3 emissions based on primary dataScope 3 emissions based on spend data(EEIO or supplier allocations)Scope 3 verified emissions(FERA,waste,business air travel in all years;upstream transportation and distribution from 2022 onwar

98、d)N/A:These Scope 3 categories are not applicable to Gilead in alignment with guidance found in the current Greenhouse Gas Protocol(GHGP).Upstream leased assets:all leased assets are reported in Gileads Scope 1 and 2 emissions.Processing of sold products:Gilead products are not subject to further pr

99、ocessing after they are sold.Use of sold products:The use of Gileads therapeutic products does not cause GHG emissions.Downstream leased assets:Gilead does not sublet sites.Franchises:Gilead does not have franchises.Updated EEIO emissions methodology is reflected in 2019/2022/2023.2020 and 2021 EEIO

100、 emissions may be updated in the future.Due to the immateriality of these emissions,the End of Life Treatment of Sold Products emissions have been held flat year over year.1234 56E N V I R O N M E N TA L DATAG R ISAS BSUPPLY C HAINTAXA BO U TRESPONSIBILITY172024 RESPONSIBLE BUSINESS AND IMPACT REPOR

101、T:REPORTING APPENDIXINNOVATE for ImpactENERGY CONSUMPTION Megawatt hour(MWh)20192020202120222023Total Energy Consumption from Renewable Sources*89,90097,85494,078125,639133,759Purchased Electricity89,79397,66889,575115,475122,543Mobile Fuels5693361,8523,206Self-generation511774,1678,3128,010Total En

102、ergy Consumption from Nonrenewable Sources358,887340,883374,597354,689341,049Distillate Fuel Oil472217142308234Mobile Fuels79,54644,05356,99475,70281,433Natural Gas185,116200,491211,478197,729185,450Other Stationary8561716Purchased Electricity93,74595,935105,83880,80873,616Purchased Heat/Steam/Cooli

103、ng182139125300Total Combined Energy Consumption 448,788438,737468,675480,327474,807Data Coverage(as a percentage of global full-time employees)100%100%100%100%100%BUILDING ENERGY INTENSITY Kilowatt hours per square foot(kWh/sq.ft.)20192020202120222023Total Energy Intensity from Renewable Sources 12.

104、4 12.211.414.615.2Total Energy Intensity from Nonrenewable Sources 38.7 36.938.733.030.3Total Building Energy Intensity 51.1 49.1 50.147.645.5*This figure includes renewable energy from self-generation,contracts with electricity suppliers and unbundled energy attribute certificates(EACs)in alignment

105、 with RE100 technical guidance.E N V I R O N M E N TA L DATAG R ISAS BSUPPLY C HAINTAXA BO U TRESPONSIBILITY182024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactNONHAZARDOUS WASTE DISPOSAL Metric tons(mt)20192020202120222023Composting2,7102,5212,0791,6231,769Incineratio

106、n27303489Incineration with Energy Recovery07969135184Landfill6,5624,1743,7123,2782,693Other4370000Recycling4,9934,1093,4693,9464,058Reuse015460115Total Nonhazardous Waste14,72910,9139,4179,0508,828Data Coverage(as a percentage of global full-time employees)83%88%92%96%94%HAZARDOUS WASTE DISPOSAL Met

107、ric tons(mt)20192020202120222023Deep Well Injection1,6802,0421,6041,4911,092Incineration1,0491,020817919881Incineration with Energy Recovery8861,0069587391,673Landfill0195246601142Neutralization01011718Other53000Recovery41914811Recycling573336632225Total Hazardous Waste3,6814,3194,0054,1973,842Data

108、Coverage(as a percentage of global full-time employees)100%100%100%100%100%E N V I R O N M E N TA L DATAG R ISAS BSUPPLY C HAINTAXA BO U TRESPONSIBILITY192024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactWATER USAGE Megaliters(ML)20192020202120222023Fire/Life Safety Wa

109、ter0.30.70.40.50.6Indoor Water575.9580.1702.1712.6640.3Irrigation Water77.7112.672.792.582.0Total Water Usage654693775806723Data Coverage(as a percentage of global full-time employees)78%88%88%89%88%FLOOR AREA Square feet(sq.ft.)20192020202120222023Total Area of Facilities Under Operational Control7

110、.22M8.05M8.21M8.46M8.58ME N V I R O N M E N TA L DATAG R ISAS BSUPPLY C HAINTAXA BO U TRESPONSIBILITY202024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactDISCLOSURE TITLEDESCRIPTION/LOCATIONGENERAL DISCLOSURES2-1Organizational details Gilead 2024 Responsible Business an

111、d Impact Report,Creating Possible:About Gilead,Page 11 Gilead 2024 Form 10-K,Item 1.Business2-2Entities included in the organizations sustainability reporting Gilead 2024 Form 10-K,Exhibit 21.1.Subsidiaries of Gilead Sciences,Inc.2-3Reporting period,frequency and contact point Gilead 2024 Responsibl

112、e Business and Impact Report,About This Report,Page 2 public_2-4Restatements of information Not Applicable2-5External assurance Gilead Website,Environmental Sustainability Data Performance Tables2-6Activities,value chain and other business relationships Gilead 2024 Responsible Business and Impact Re

113、port,Creating Possible,Our Approach to Responsible Business,Pages 12-13;Sustaining Our Shared Planet,Reducing Emissions From Our Value Chain,Page 65 Gilead 2024 Form 10-K,Item 1.Business;Item 1A.Risk Factors Gilead Supplier Code of Conduct2-7Employees Gilead 2024 Responsible Business and Impact Repo

114、rt,Empowering People and Communities,Reporting Workforce Data,Page 542-9Governance structure and composition Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Active Leadership and Board Involvement,Pages 3-4 Gilead Website,Board Governance and Committees Gilead 2025 Proxy Statem

115、ent,Board Leadership Structure,Pages 32-35;Committees of Our Board of Directors,Pages 36-39GRI IndexE NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTAXA BO U TRESPONSIBILITY212024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactDISCLOSURE TITLEDESCRIPTION/LOCATION2-10Nomina

116、tion and selection of the highest governance body Gilead 2025 Proxy Statement,Board Refreshment and Director Nomination Process,Pages 17-19;Nominees,Pages 20-262-11Chair of the highest governance body Gilead 2025 Proxy Statement,The Gilead Board of Directors,Pages 14-17 Gilead Sciences Board Guideli

117、nes2-12Role of the highest governance body in overseeing the management of impacts Gilead Nominating and Corporate Governance Committee Charter2-13Delegation of responsibility for managing impacts Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Gileads ESG Governance Strcuture,

118、Page 42-14Role of the highest governance body in sustainability reporting Gileads Board of Directors reviews and approves Gileads ESG material topics;the CEO and Chairman of the Board reviews and approves the Gilead Responsible Business and Impact Report.2-15Conflicts of interest Gilead 2025 Proxy S

119、tatement,Conflicts of Interest,Page 40 Gilead Code of Ethics,Page 14 Gilead Anti-Bribery and Anti-Corruption Policy2-16Communication of critical concerns Gilead Stockholder Communications with the Board Gilead Code of Ethics,Page 252-17Collective knowledge of the highest governance body Gilead 2025

120、Proxy Statement,Board Overview,Pages 14-172-18Evaluation of the performance of the highest governance body Gilead 2025 Proxy Statement,Board Evaluations,Page 342-19Remuneration policies Gilead 2025 Proxy Statement,Compensation of Non-Employee Board Members,Pages 41-43 Gilead 2025 Proxy Statement,Exe

121、cutive Compensation,Pages 50-58E NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTAXA BO U TRESPONSIBILITY222024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactDISCLOSURE TITLEDESCRIPTION/LOCATION2-20Process to determine remuneration Gilead 2025 Proxy Statement,Compensation

122、of Non-Employee Board Members,Pages 41-43 Gilead 2025 Proxy Statement,Executive Compensation,Pages 50-582-21Annual total compensation ratio Gilead 2025 Proxy Statement,CEO Pay Ratio,Page 712-22Statement on sustainable development strategy Gilead 2024 Responsible Business and Impact Report,A Letter F

123、rom Our Chairman and CEO,Pages 3-4;The Courage to End an Epidemic,Pages 5-8;Creating Possible,Our Approach to Responsible Business,Pages 12-13;Sustaining Our Shared Planet,A Scalable Strategy for Sustainable Progress,Page 632-23Policy commitments The Gilead Code of Ethics is approved by our Board of

124、 Directors.Employees are required to read and abide by our Code of Ethics.See also:Gilead Website,Policies and Procedures See also:Gilead Website,Governance Documents2-24Embedding policy commitments The Gilead Code of Ethics is approved by our Board of Directors.Employees are required to read and ab

125、ide by our Code of Ethics.See also:Gilead Website,Policies and Procedures See also:Gilead Website,Governance Documents2-25Process to remediate negative impacts Gilead 2024 Responsible Business and Impact Report,Sustaining Our Shared Planet,Pages 61-79 Gilead Website,Report an Adverse Event Gilead 20

126、24 Form 10-K,Item 1A.Risk Factors Gilead Website,Consumer Product Safety 2-26Mechanisms for seeking advice and raising concerns Gilead Code of Ethics,Page 252-27Compliance with laws and regulations Gilead 2024 Form 10-K,Note 13.Commitments and Contingencies,Legal Proceedings2-28Membership associatio

127、ns Gilead is a member of many industry associations,including the following:Pharmaceutical Research and Manufacturers of America,Biotechnology Innovation Organization,International Federation of Pharmaceutical Manufacturers&Associations,American Chemical Society Green Chemistry Institute Pharmeceuti

128、cal Roundtable,International Aids Society,RE100 and EV100.E NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTAXA BO U TRESPONSIBILITY232024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactDISCLOSURE TITLEDESCRIPTION/LOCATION2-29Approach to stakeholder engagement Gilead 2024 R

129、esponsible Business and Impact Report,The Courage to End an Epidemic,Pages 5-8;Advancing Access and Health Equity,Pages 31-43;Empowering People and Communities,Pages 45-59;Sustaining Our Shared Planet,Pages 61-82 Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Management,Stakeh

130、older Engagement and Materiality,Pages 5-62-30Collective bargaining agreements All Gilead employees in Austria,Belgium,Brazil,Spain,France and Italy(6%of worldwide workforce)were subject to collective bargaining agreements in 2024.MATERIAL TOPICS3-1Process to determine material topics Gilead 2024 Re

131、sponsible Business and Impact Report:Reporting Appendix,Management,Stakeholder Engagement and Materiality,Pages 5-63-2List of material topics Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Management,Stakeholder Engagement and Materiality,Pages 5-63-3Management of material top

132、ics Gilead 2024 Form 10-K Gilead Website,ESG Focus AreasECONOMIC PERFORMANCE201-1Direct economic value generated and distributed Gilead 2024 Form 10-K,Item 8.Financial Statements and Supplementary Data201-2Financial implications and other risks and opportunities due to climate change Gilead 2024 CDP

133、 Corporate Questionnaire Response Task Force on Climate-related Financial Disclosures Summary Report201-3Defined benefit plan obligations and other retirement plans Gilead 2024 Form 10-K,Deferred Compensation,Page 91201-4Financial assistance received from government Gilead 2024 Form 10-K,Income Taxe

134、s,Pages 91-92E NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTAXA BO U TRESPONSIBILITY242024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactDISCLOSURE TITLEDESCRIPTION/LOCATIONINDIRECT ECONOMIC IMPACTS3-3Management of material topics Gilead 2024 Responsible Business and Im

135、pact Report,The Courage to End an Epidemic,Pages 5-8;Advancing Access and Health Equity,Pages 31-43;Empowering People and Communities,Pages 45-59,Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Quantifying Supplier Inclusion Economic Impact,Page 8 Gilead Website,ESG Focus Areas

136、203-1Infrastructure investments and services supported Gilead 2024 Responsible Business and Impact Report,The Courage to End an Epidemic,Pages 5-8;Advancing Access and Health Equity,Pages 31-43;Empowering People and Communities,Pages 45-59,Gilead 2024 Responsible Business and Impact Report:Reporting

137、 Appendix,Quantifying Supplier Inclusion Economic Impact,Page 8203-2Significant indirect economic impacts Gilead 2024 Responsible Business and Impact Report,The Courage to End an Epidemic,Pages 5-8;Advancing Access and Health Equity,Pages 31-43;Empowering People and Communities,Pages 45-59,Gilead 20

138、24 Responsible Business and Impact Report:Reporting Appendix,Quantifying Supplier Inclusion Economic Impact,Page 8PROCUREMENT PRACTICES3-3Management of material topics Gilead 2024 Responsible Business and Impact Report,Sustaining Our Shared Planet,Reducing Emissions from Our Value Chain,Pages 65-66

139、Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Our Supply Chain Investments,Pages 7-8 Gilead Supplier Code of Conduct Gilead Website,Supplier Information204-1Proportion of spending on local suppliers In 2022,44%of our direct spend was with local suppliers,which Gilead defines

140、as the state of California.Gileads most significant location of operation is its headquarters in Foster City,California,and we have a large presence in California.In this instance,we define“local”as any supplier that has identified its company headquarters as located in the state of California.E NVI

141、R O NM E NTAL DATAG R ISAS BSUPPLY C HAINTAXA BO U TRESPONSIBILITY252024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactDISCLOSURE TITLEDESCRIPTION/LOCATIONANTI-CORRUPTION3-3Management of material topics Gilead Anti-Bribery and Anti-Corruption Policy Gilead Website,ESG F

142、ocus Areas205-1Operations assessed for risks related to corruption Gilead performs internal and external audits to monitor for compliance with regulatory and company policies.205-2Communication and training about anti-corruption policies and procedures In 2024,anti-bribery and anti-corruption traini

143、ngs were provided to our Audit Committee,which is a subset of our Board of Directors,and regional business partners and distributors located in Europe,Asia,Africa,North America and South America.205-3Confirmed incidents of corruption and actions taken In 2024,there were no findings of corruption,ant

144、i-competitive behavior,violations of anti-trust and monopoly legislation,or other healthcare compliance violations from any government body.ANTI-COMPETITIVE BEHAVIOR3-3Management of material topics Gilead Code of Ethics,Page 16 Gilead Website,ESG Focus Areas206-1Legal actions for anti-competitive be

145、havior,anti-trust and monopoly practices In 2024,there were no findings of corruption,anti-competitive behavior,violations of anti-trust and monopoly legislation,or other healthcare compliance violations from any government body.TAX3-3Management of material topics Gilead 2024 Responsible Business an

146、d Impact Report:Reporting Appendix,Pages 9-12 Gilead Website,ESG Focus Areas207-1Approach to tax Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Pages 9-12207-2Tax governance,control and risk management Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Pages

147、 9-12207-3Stakeholder engagement and management of concerns related to tax Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Page 10E NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTAXA BO U TRESPONSIBILITY262024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for

148、ImpactDISCLOSURE TITLEDESCRIPTION/LOCATION207-4Country-by-country reporting Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,2024 Tax and Jurisdictional Data,Pages 11-12ENERGY3-3Management of material topics Gilead 2024 Responsible Business and Impact Report,Sustaining Our Share

149、d Planet,Pages 63-70 Gilead 2024 CDP Corporate Questionnaire Response Task Force on Climate-related Financial Disclosures Summary Report Gilead Website,ESG Focus Areas302-1Energy consumption within the organization Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Environmental D

150、ata,Page 17302-2Energy consumption outside of the organization Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Environmental Data,Page 17302-3Energy intensity Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Environmental Data,Page 17302-4Reduction of energ

151、y consumption Gilead 2024 Responsible Business and Impact Report,Sustaining Our Shared Planet,Pages 67-68WATER AND EFFLUENTS3-3Management of material topics Gilead 2024 Responsible Business and Impact Report,Sustaining Our Shared Planet,Protecting Critical Water Resources,Pages 71-73 Gilead Website,

152、ESG Focus Areas303-1Interactions with water as a shared resource Gilead 2024 Responsible Business and Impact Report,Sustaining Our Shared Planet,Protecting Critical Water Resources,Pages 71-73303-5Water consumption Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Environmental D

153、ata,Page 19E NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTAXA BO U TRESPONSIBILITY272024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactDISCLOSURE TITLEDESCRIPTION/LOCATIONBIODIVERSITY3-3Management of material topics Gilead 2024 Responsible Business and Impact Report,Sus

154、taining Our Shared Planet,Connecting Biodiversity and Water Resources,Page 73 Gilead Website,ESG Focus Areas304-3Habitats protected or restored Gilead 2024 Responsible Business and Impact Report,Sustaining Our Shared Planet,Broadening Our Reach and Impact,Pages 80-82EMISSIONS3-3Management of materia

155、l topics Gilead 2024 Responsible Business and Impact Report,Sustaining Our Shared Planet,Pages 63-70 Gilead 2024 CDP Corporate Questionnaire Response Task Force on Climate-related Financial Disclosures Summary Report Gilead Website,ESG Focus Areas305-1Direct(Scope 1)GHG emissions Gilead 2024 Respons

156、ible Business and Impact Report:Reporting Appendix,Environmental Data,Page 15305-2Energy indirect(Scope 2)GHG emissions Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Environmental Data,Page 15305-3Other indirect(Scope 3)GHG emissions Gilead 2024 Responsible Business and Impac

157、t Report:Reporting Appendix,Environmental Data,Page 16305-4GHG emissions intensity Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Environmental Data,Page 15WASTE3-3Management of material topics Gilead 2024 Responsible Business and Impact Report,Sustaining Our Shared Planet,Cat

158、alyzing Materials Stewardship and Waste Reduction,Pages 74-76 Gilead Website,ESG Focus AreasE NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTAXA BO U TRESPONSIBILITY282024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactDISCLOSURE TITLEDESCRIPTION/LOCATION306-1Waste generat

159、ion and significant waste-related impacts Gilead 2024 Responsible Business and Impact Report,Sustaining Our Shared Planet,Catalyzing Materials Stewardship and Waste Reduction,Pages 74-76 Gilead 2024 Responsible Business and Impact Report,Reporting Appendix,Environmental Data,Page 18306-2Management o

160、f significant waste-related impacts Gilead 2024 Responsible Business and Impact Report,Sustaining Our Shared Planet,Catalyzing Materials Stewardship and Waste Reduction,Pages 74-76306-3Waste generated Gilead 2024 Responsible Business and Impact Report,Reporting Appendix,Environmental Data,Page 18306

161、-4Waste diverted from disposal Gilead 2024 Responsible Business and Impact Report,Reporting Appendix,Environmental Data,Page 18306-5Waste directed to disposal Gilead 2024 Responsible Business and Impact Report,Reporting Appendix,Environmental Data,Page 18SUPPLIER ENVIRONMENTAL ASSESSMENT3-3Managemen

162、t of material topics Gilead 2024 Responsible Business and Impact Report,Sustaining Our Shared Planet,Reducing Emissions from Our Value Chain,Page 65 Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Our Supply Chain Investments,Page 7 Gilead 2024 CDP Corporate Questionnaire Respo

163、nse Gilead Website,ESG Focus Areas308-1New suppliers that were screened using environmental criteria In 2024,we made progress toward our 2025 goal of securing the signatures of 90%of our direct and indirect suppliers(based on spend)to our Supplier Code of Conduct.308-2Negative environmental impacts

164、in the supply chain and actions taken Gilead 2024 Responsible Business and Impact Report,Sustaining Our Shared Planet,Reducing Emissions from Our Value Chain,Page 65 Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Our Supply Chain Investments,Page 7E NVIR O NM E NTAL DATAG R IS

165、AS BSUPPLY C HAINTAXA BO U TRESPONSIBILITY292024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactDISCLOSURE TITLEDESCRIPTION/LOCATIONEMPLOYMENT3-3Management of material topics Gilead 2024 Responsible Business and Impact Report,Empowering People and Communities,Pages 45-56

166、 Gilead Website,ESG Focus Areas401-1New employee hires and employee turnover Gilead 2024 Responsible Business and Impact Report,Empowering People and Communities,Reporting Workforce Data,Page 54401-2Benefits provided to full-time employees that are not provided to temporary or part-time employees Gi

167、lead 2024 Responsible Business and Impact Report,Empowering People and Communities,Benefits and Wellness,Page 52401-3Parental leave Gilead 2024 Responsible Business and Impact Report,Empowering People and Communities,Global Parental Leave Data,Page 55OCCUPATIONAL HEALTH AND SAFETY3-3Management of ma

168、terial topics Gilead 2024 Responsible Business and Impact Report,Empowering People and Communities,Health and Safety,Page 56 Gilead Website,ESG Focus Areas403-3Occupational health services Gilead employees have access to licensed occupational health services(OHS)during working hours,and we are able

169、to arrange transportation to OHS locations.OHS providers converse in the official country language.OHS and Gilead strive to comply with applicable privacy laws and local requirements for protecting personal health information.403-5Worker training on occupationalhealth and safety Gilead uses hazards

170、exposure assessments to identify general and specific OHS trainings.We seek to align training content with applicable regulatory standards and that trainers meet local competency requirements.Trainings are provided free of charge and during paid working hours.403-6Promotion of worker health Gilead 2

171、024 Responsible Business and Impact Report,Empowering People and Communities,Our Total Rewards Benefits,Page 52E NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTAXA BO U TRESPONSIBILITY302024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactDISCLOSURE TITLEDESCRIPTION/LOCATIO

172、N403-9Work-related injuries Gilead 2024 Responsible Business and Impact Report,Empowering People and Communities,Health and Safety,Page 56403-10Work-related ill health Gilead 2024 Responsible Business and Impact Report,Empowering People and Communities,Health and Safety,Page 56TRAINING AND EDUCATION

173、3-3Management of material topics Gilead 2024 Responsible Business and Impact Report,Empowering People and Communities,Developing Our People Leaders,Page 47;Maximizing Performance and Growth,Page 48 Gilead Website,ESG Focus Areas404-2Programs for upgrading employee skills and transition assistance pr

174、ograms Gilead 2024 Responsible Business and Impact Report,Empowering People and Communities,Developing Our People Leaders,Page 47;Maximizing Performance and Growth,Page 48404-3Percentage of employees receiving regular performance and career development reviews All Gilead employees are expected to re

175、ceive regular performance and career development reviews.DIVERSITY AND EQUAL OPPORTUNITY3-3Management of material topics Gilead 2024 Responsible Business and Impact Report,Empowering People and Communities,Employee Resource Groups,Page 50;Advancing Disability Inclusion,Page 50 Gilead Website,ESG Foc

176、us Areas405-1Diversity of governance bodiesand employees Gilead 2024 Responsible Business and Impact Report,Empowering People and Communities,Reporting Workforce Data,Page 54 Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Page 3 Gilead 2025 Proxy Statement,The Gilead Board of

177、Directors,Pages 14-17405-2Ratio of basic salary and remunerationof women to men Gileads salary ratio for women to men globally is 99.90:100.00.E NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTAXA BO U TRESPONSIBILITY312024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactDIS

178、CLOSURE TITLEDESCRIPTION/LOCATIONNON-DISCRIMINATION3-3Management of material topics Gilead Code of Ethics,Pages 8-9 Gilead Website,ESG Focus Areas406-1Incidents of discriminationand corrective actions taken Gilead tracks incidents of discrimination and corrective actions taken;however we do not publ

179、icly report on this due to employee privacy concerns and any pending legal or regulatory actions (information is subject to specific confidentiality constraints).FREEDOM OF ASSOCIATION AND COLLECTIVE BARGAINING3-3Management of material topics Supplier Code of Conduct Gilead Website,Supplier Informat

180、ion407-1Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk Supplier Code of ConductCHILD LABOR3-3Management of material topics Supplier Code of Conduct Gilead Website,Supplier Information408-1Operations and suppliers at significantrisk for

181、incidents of child labor Supplier Code of ConductFORCED OR COMPULSORY LABOR3-3Management of material topics Supplier Code of Conduct Gilead Website,Supplier Information409-1Operations and suppliers at significantrisk for incidents of forced orcompulsory labor Supplier Code of ConductE NVIR O NM E NT

182、AL DATAG R ISAS BSUPPLY C HAINTAXA BO U TRESPONSIBILITY322024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactDISCLOSURE TITLEDESCRIPTION/LOCATIONLOCAL COMMUNITIES3-3Management of material topics Gilead 2024 Responsible Business and Impact Report,Empowering People and Com

183、munities,Lifting Our Local Communities,Pages 57-59;Sustaining Our Shared Planet,Broadening Our Reach and Impact,Pages 80-82 Gilead Website,ESG Focus Areas413-1Operations with local communityengagement,impact assessments,and development programs Gilead 2024 Responsible Business and Impact Report,Sust

184、aining Our Shared Planet,Broadening Our Reach and Impact,Pages 80-82SUPPLIER SOCIAL ASSESSMENT3-3Management of material topics Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Our Supply Chain Investments,Pages 7-8 Supplier Code of Conduct414-1New suppliers that were screenedusi

185、ng social criteria In 2024,we made progress toward our 2025 goal of securing the signatures of 90%of our direct and indirect suppliers(based on spend)to our Supplier Code of Conduct.Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Our Supply Chain Investments,Pages 7-8414-2Negat

186、ive social impacts in the supplychain and actions taken Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Our Supply Chain Investments,Pages 7-8PUBLIC POLICY3-3Management of material topics Gilead Website,U.S.Public Policy Engagement415-1Political contributions Gilead Website,U.S

187、.Public Policy EngagementE NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTAXA BO U TRESPONSIBILITY332024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactDISCLOSURE TITLEDESCRIPTION/LOCATIONCUSTOMER HEALTH AND SAFETY3-3Management of material topics Gilead Website,Report an A

188、dverse Event Gilead Website,ESG Focus Areas See also GRI 2-25415-1Assessment of the health and safety impacts of product and service categories These assessments are included in the downloadable Prescribing Information and Patient Information documents on our website.Gilead Website,Medicines Gilead

189、Website,Consumer Product SafetyMARKETING AND LABELING3-3Management of material topics See GRI 417-1417-1Requirements for product andservice information and labeling Instructions for the safe use of our medicines are included in the downloadable Prescribing Information and Patient Information documen

190、ts on our website.Gilead Website,Consumer Product Safety417-2Incidents of noncompliance concerning product and service information and labeling Gilead did not receive from any government body any warnings,fines or penalties in 2024 related to our labeling practices.417-3Incidents of noncompliance co

191、ncerning marketing communications Gilead did not receive from any government body any warnings,fines or penalties in 2024 related to our marketing communications.CUSTOMER PRIVACY3-3Management of material topics Gilead Website,Privacy Statement418-1Substantiated complaints concerningbreaches of custo

192、mer privacy and losses of customer data Gilead did not have any substantiated complaints concerning losses of customer data in 2024.E NVIR O NM E NTAL DATAG R ISAS BSUPPLY C HAINTAXA BO U TRESPONSIBILITY342024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactSASB IndexACCO

193、UNTING METRICCATEGORYUNIT OF MEASURECODEDESCRIPTION/LOCATIONSAFETY OF CLINICAL TRIAL PARTICIPANTSDiscussion,by region,of management process for ensuring quality and patient safety duringclinical trialsDiscussion and AnalysisN/AHC-BP-210a.1Informed Consent:A document given to those considering enroll

194、ing in a clinical trial by the research team.It describes the rights of a study participant and provides details about the trial,such as its purpose,duration,required procedures and key contacts.Risks and potential benefits are explained in the informed consent document.Institutional Review Board/Et

195、hics Committee(IRB/EC):A committee at hospitals and medical institutions whose purpose is to protect the rights and welfare of study participants recruited to take part in research activities at their locations.In accordance with the Food and Drug Administration(FDA)and the European Medicines Agency

196、(EMA)regulations,an IRB/EC has the authority to approve,require modifications to or disapprove research trials.Data Safety Monitoring Board:A group of qualified individuals who monitor the clinical study to ensure the safety of trial participants,as well as the validity and integrity of the study da

197、ta.For more information,see our Guide to Clinical Trials.Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countriesQuantitativePresentation currencyHC-BP-210a.3When public disclosure criteria are met,monetary losses as a result of legal p

198、roceedings associated with clinical trials in developing countries are included in Gilead 2024 Form 10-K,Note 13,Commitments and Contingencies,Legal Proceedings,Pages 84-87.E NVIR O NM E NTAL DATAG R ISA SBSUPPLY C HAINTAXA BO U TRESPONSIBILITY352024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING

199、APPENDIXINNOVATE for ImpactACCOUNTING METRICCATEGORYUNIT OF MEASURECODEDESCRIPTION/LOCATIONACCESS TO MEDICINESDescription of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine IndexDiscussion and Anal

200、ysisN/AHC-BP-240a.1Gilead 2024 Responsible Business and Impact Report,The Courage to End an Epidemic,Pages 5-8;Advancing Access and Health Equity,Pages 32-43List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme(PQP)Discussion and A

201、nalysisN/AHC-BP-240a.2Gilead has five products on the WHO List of Prequalified Medicinal Products including Lenacapavir,Remdesivir,Amphotericin B,Sofosbuvir/Velpatasvir and Tenofovir disoproxil fumarate.DRUG SAFETYProducts listed in publicmedical product safety or adverse event alert databasesDiscus

202、sion and AnalysisN/AHC-BP-250a.1Gilead collects Adverse Events from sources globally and assesses those data on an ongoing basis,both on the individual case level as well as in aggregate,and reports those data to agencies worldwide in its effort to comply with applicable safety regulations.Furthermo

203、re,Gilead has robust and comprehensive processes in place for the detection of potential new safety signals with our products in development and on the market as well as for disclosure,as applicable,to agencies,physicians and patients.FDA Adverse Event Reporting System(FAERS)(1)Number of recalls iss

204、ued,(2)total units recalledQuantitativeNumberHC-BP-250a.3Gilead issued a voluntary recall of one lot of Veklury(remdesivir).E NVIR O NM E NTAL DATAG R ISA SBSUPPLY C HAINTAXA BO U TRESPONSIBILITY362024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactACCOUNTING METRICCATEG

205、ORYUNIT OF MEASURECODEDESCRIPTION/LOCATIONTotal amount of productaccepted for takeback,reuse,or disposalQuantitativeMetric tonnes(t)HC-BP-250a.4Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Helping to Provide Access to Genuine Medicines,Page 8COUNTERFEIT DRUGSDescription of m

206、ethods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeitingDiscussion and AnalysisN/AHC-BP-260a.1See Gileads full response to SASB Counterfeit Drugs.(HC-BP-260a.1 HC-BP-260a.3),Gilead 2024 Responsible Business and Impact Report:Reporting A

207、ppendix,Helping to Provide Access to Genuine Medicines,Page 8Discussion of process for alerting customers and business partners to potential or known risks associated with counterfeit productsDiscussion and AnalysisN/AHC-BP-260a.2See Gileads full response to SASB Counterfeit Drugs.(HC-BP-260a.1 HC-B

208、P-260a.3),Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Helping to Provide Access to Genuine Medicines,Page 8Number of actions that led to raids,seizure,arrests,or filing of criminal charges related to counterfeit productsQuantitativeNumberHC-BP-260a.3See Gileads full respons

209、e to SASB Counterfeit Drugs.(HC-BP-260a.1 HC-BP-260a.3),Gilead 2024 Responsible Business and Impact Report:Reporting Appendix,Helping to Provide Access to Genuine Medicines,Page 8E NVIR O NM E NTAL DATAG R ISA SBSUPPLY C HAINTAXA BO U TRESPONSIBILITY372024 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPO

210、RTING APPENDIXINNOVATE for ImpactACCOUNTING METRICCATEGORYUNIT OF MEASURECODEDESCRIPTION/LOCATIONETHICAL MARKETINGTotal amount of monetarylosses as a result of legalproceedings associated with false marketing claimsQuantitativePresentationcurrencyHC-BP-270a.1When public disclosure criteria are met,m

211、onetary losses as a result of legal proceedings associated with false marketing claims are included in Gilead 2024 Form 10-K,Note 13,Commitments and Contingencies,Legal Proceedings,Pages 84-87.Description of code of ethics governing promotion of off-label use of productsDiscussion and AnalysisN/AHC-

212、BP-270a.2We promote our products in compliance with the applicable Gilead Business Conduct Manuals and related policies,which incorporate the laws,regulations,industry codes and practices that govern the pharmaceutical industry and our company.EMPLOYEE RECRUITMENT,DEVELOPMENT&RETENTIONDiscussion of

213、talentrecruitment and retentionefforts for scientists andresearch and development staffDiscussion and AnalysisN/AHC-BP-330a.1Gilead 2024 Responsible Business and Impact Report,Empowering People and Communities,Pages 46-53(1)Voluntary and(2)involuntary turnoverrate for:(a)executives/senior managers,(

214、b)mid-level managers,(c)professionals,and(d)all othersQuantitativePercentage(%)HC-BP-330a.2Gilead 2024 Responsible Business and Impact Report,Empowering People and Communities,Reporting Workforce Data,Page 54E NVIR O NM E NTAL DATAG R ISA SBSUPPLY C HAINTAXA BO U TRESPONSIBILITY382024 RESPONSIBLE BU

215、SINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactACCOUNTING METRICCATEGORYUNIT OF MEASURECODEDESCRIPTION/LOCATIONBUSINESS ETHICSTotal amount of monetarylosses as a result of legalproceedings associatedwith corruption and briberyQuantitativePresentationcurrencyHC-BP-510a.1When public dis

216、closure criteria are met,monetary losses as a result of legal proceedings associated with corruption and bribery are included in Gilead 2024 Form 10-K,Note 13,Commitments and Contingencies,Legal Proceedings,Pages 84-87.Description of code of ethics governing interactions with health care professiona

217、lsDiscussion and AnalysisN/AHC-BP-510a.2We work with healthcare professionals,patient organizations,payer bodies and others in the healthcare community for the right reasons,in a transparent and ethical way.We strive to comply with the applicable laws,regulations,industry codes and practices that go

218、vern the pharmaceutical industry and our company(collectively,“Industry Standards”)in the promotion of prescription medicines.Our expectations:Ensure that we always have a clear,legitimate and appropriate business purpose for all our interactions.Promote our products in compliance with the applicabl

219、e Gilead Business Conduct Manuals and related policies,which incorporate the Industry Standards.Ensure that all information and materials are accurate,fair,balanced,not misleading and shared appropriately.Do not provide anything of value to inappropriately influence a decision to approve,reimburse,p

220、rescribe,purchase or recommend a Gilead product.Read,understand and follow the applicable Gilead Business Conduct Manuals and related policies required for you to perform your role.For more information,see our Code of Ethics.E NVIR O NM E NTAL DATAG R ISA SBSUPPLY C HAINTAXA BO U TRESPONSIBILITY3920

221、24 RESPONSIBLE BUSINESS AND IMPACT REPORT:REPORTING APPENDIXINNOVATE for ImpactE NVIR O NM E NTAL DATAG R ISA SBSUPPLY C HAINTAXA BO U TRESPONSIBILITYACCOUNTING METRICCATEGORYUNIT OF MEASURECODEDESCRIPTION/LOCATIONACTIVITY METRICSNumber of patients treatedQuantitativeNumberHC-BP-000.ACertain patient

222、 reach numbers are reported on the following pages:Gilead 2024 Responsible Business and Impact Report,Innovating Scientific Solutions,Pages 19,24 and 27-28;Advancing Access and Health Equity,Pages 33,35 and 43 Number of drugs(1)in portfolio and(2)in researchand development(Phases 1-3)QuantitativeNum

223、berHC-BP-000.B(1)A list of our primary revenue-generating products approved in the U.S.was included in Gilead 2024 Form 10-K,Item 1.Business.(2)A detailed list of our R&D pipeline can be found on the Pipeline page of our company website.PHOTOGRAPHYAll images appearing here are either the property of Gilead or used with permission from their respective owners.On Our Cover:Edward Son,Corporate Legal 2025 Gilead Sciences,Inc.All rights reserved.